Barashi Rami, Gabarin Mustafa, Arow Ziad, Hilu Ranin, Losin Ilya, Novikov Ivan, Abd El Hai Karam, Arnson Yoav, Neuman Yoram, Pesis Koby, Jebara Ziyad, Pereg David, Koifman Edward, Assali Abid, Vaknin-Assa Hana
Department of Cardiology, Meir Medical Center, Kfar Saba 4428164, Israel.
School of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
J Clin Med. 2025 Aug 2;14(15):5449. doi: 10.3390/jcm14155449.
: Aortic stenosis (AS) is the most common valvular heart disease, associated with poor outcomes if left untreated. Current guidelines recommend that transcatheter aortic valve implantation (TAVI) procedures be performed in hospitals with an on-site cardiac surgery unit due to potential complications requiring surgical intervention. : Based on our experience, we evaluated the feasibility and outcomes of implementing a TAVI program in a cardiology department without an on-site cardiac surgery unit, in collaboration with a remote hospital for surgical backup. : The TAVI program involved pre- and post-procedural evaluations conducted at Meir Medical Center (Kfar Saba, Israel) with a remote surgical team available. The study population included 149 consecutive patients with severe aortic stenosis treated at the Meir valve clinic between November 2019 and December 2023. Procedures were performed by the center's interventional cardiology team. : The mean age of the 149 patients was 80 ± 6 years, and 75 (50%) were female. The average STS score was 4.3, and the EuroSCORE II was 3.1. Among the patients, 68 (45%) were classified as New York Heart Association (NYHA) class III-IV. The valve types used included ACURATE neo2 (57 patients, 38%), Edwards SAPIEN 3 (43 patients, 28%), Evolut-PRO (41 patients, 27%), and Navitor (7 patients, 4%). There were no cases of moderate to severe paravalvular leak and no elevated post-implantation gradients, and there was no need for urgent cardiac surgery. One case of valve embolization was successfully managed percutaneously during the procedure. In-hospital follow-up revealed no deaths and only one major vascular complication. At one-year follow-up, six patients had died, with only one death attributed to cardiac causes. : Our findings support the safe and effective performance of transfemoral TAVI in cardiology departments without on-site cardiac surgery, in collaboration with a remote surgical team. Further prospective, multicenter studies are warranted to confirm these results and guide broader clinical implementation of this practice.
主动脉瓣狭窄(AS)是最常见的心脏瓣膜病,若不治疗,预后较差。当前指南建议,由于可能出现需要外科干预的并发症,经导管主动脉瓣植入术(TAVI)应在设有现场心脏外科的医院进行。基于我们的经验,我们评估了在没有现场心脏外科的心脏病科实施TAVI项目并与远程医院协作以获得手术支持的可行性和结果。TAVI项目包括在梅厄医疗中心(以色列卡法萨巴)进行术前和术后评估,并配备远程手术团队。研究人群包括2019年11月至2023年12月期间在梅厄瓣膜诊所接受治疗的149例连续性重度主动脉瓣狭窄患者。手术由该中心的介入心脏病学团队进行。149例患者的平均年龄为80±6岁,75例(50%)为女性。平均胸外科医师协会(STS)评分是4.3,欧洲心脏手术风险评估系统(EuroSCORE)II评分为3.1。患者中,68例(45%)被归类为纽约心脏协会(NYHA)III-IV级。使用的瓣膜类型包括ACURATE neo2(57例患者,38%)、爱德华SAPIEN 3(43例患者,28%)、Evolut-PRO(41例患者,27%)和Navitor(7例患者,4%)。没有中重度瓣周漏病例,植入后梯度也未升高,且无需紧急心脏手术。1例瓣膜栓塞在手术过程中经皮成功处理。住院随访显示无死亡病例,仅1例严重血管并发症。在1年随访时,6例患者死亡,仅1例死亡归因于心脏原因。我们的研究结果支持在没有现场心脏外科的心脏病科与远程手术团队协作安全有效地进行经股动脉TAVI。有必要进行进一步的前瞻性多中心研究以证实这些结果并指导该实践更广泛的临床应用。